Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
株式のランク #41014
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
株価
$0.00185055
時価総額
$48.29K
変化(1日)
-3.55%
変化(1年)
30.31%
GB
取引 Nuformix plc (NFX)

カテゴリー

Nuformix plc(NFX)の利益
Mar 2026 時点の利益 TTM: $-857.89K
Nuformix plc の最新の財務報告によると、同社の現在の利益は $-857.89K です。2024 年には $-4.88M の利益を上げ、これは 2023 年の利益 $-754.56K と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Nuformix plc の利益の推移(2014 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-857.89K -3.39%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -614,967.33%
US
$-3.09B 359,735.34%
US
$-4.02B 468,046.88%
AU
$1.95B -227,477.01%
NL
- -
CH